ALSO NOTED: Oragenics trial on hold; Epix gains $3M milestone; More bad new for Novartis; and much more...

> An early-stage safety trial of a cavity-prevention therapy from Oragenics has been placed on hold by U.S. regulators. Report

> Epix Pharmaceuticals will pick up a $3 million payment from GlaxoSmithKline on its discovery of three new drug discovery candidates. Release

> Biopartners says a late-stage trial of its recombinant human growth hormone--a biosimilar named Valtropin--has demonstrated equivalent safety and efficacy to its reference product. Release

> The FDA has accepted GSK's BLA for Rotarix for review. Report

> Alpine Biomed has named John Arnott, a former officer with Hospira, CEO. Release

> arGentis Pharmaceuticals has inked an agreement with The University of Tennessee Research Foundation to license the intellectual property surrounding the use of solubilized type 1 native bovine collagen as a treatment for systemic sclerosis (SSc or systemic scleroderma) and other fibrosing diseases. Release

> Poor Novartis--the blows keep coming. The National Cancer Institute has nuked a study designed to determine whether letrozole, a breast cancer drug made by the company, might actually prevent cancer. FiercePharma

> In the two weeks since the FDA told Glaxo to slap a heart attack warning label on Avandia, prescriptions slid by 40 percent, and now the drug maker appears set to slash its Avandia sales force. FiercePharma

> Researchers have found a new target that may be the key to raising levels of "good" cholesterol--a hot topic in drug discovery circles. FierceBioresearcher

And Finally... As Hispanics grow more acculturated in the U.S., their use of illegal drugs is rising. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.